VA Augmentation and Switching Treatments for Improving Depression Outcomes

NCT01421342 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1522

Enrollment

FED

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Switching: Bupropion-SR
DRUG: Augmenting: Antidepressant + Bupropion-SR
DRUG: Augmenting: Antidepressant + Aripiprazole

Sponsor

VA Office of Research and Development